Array Biopharma (ARRY) Tops Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $5.30 +14.22%
EPS Growth %: -70.0%
Financial Fact:
Total operating expenses: 63.27M
Today's EPS Names:
ATS, SICP, FTCO, More
EPS Growth %: -70.0%
Financial Fact:
Total operating expenses: 63.27M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Array Biopharma (NASDAQ: ARRY) reported Q4 EPS of ($0.09), $0.07 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $12.3 million versus the consensus estimate of $10.29 million.
For earnings history and earnings-related data on Array Biopharma (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Netflix gains after Ackman endorsement and AI feature launch
- Mizuho: 'On data centers, we believe state debate centers on water use and 'bring your own power', both favorable for BE'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
